A Soxhlet Extract of Gongronema latifolium

Retains Moderate Blood Glucose Lowering Effect and

Produces Structural Recovery in the Pancreas of STZ-Induced Diabetic Rats by Al-Hindi, Bassel et al.
medical
sciences
Article
A Soxhlet Extract of Gongronema latifolium
Retains Moderate Blood Glucose Lowering Effect and
Produces Structural Recovery in the Pancreas of
STZ-Induced Diabetic Rats
Bassel Al-Hindi 1,*, Nor A. Yusoff 1,2, Item J. Atangwho 3, Mariam Ahmad 1, Mohd Z. Asmawi 1
and Mun F. Yam 1,*
1 School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11700 Minden, Penang, Malaysia;
noradlinyusoff@yahoo.com (N.A.Y.); mariam@usm.my (M.A.); amzaini@usm.my (M.Z.A.)
2 Cluster of Integrative Medicine, Advanced Medical and Dental Institute, 13200 Penang, Malaysia
3 Department of Biochemistry, College of Medical Sciences, University of Calabar, P. M. B. 1115 Calabar,
Nigeria; dratangwho@gmail.com
* Correspondence: basselalhindi@yahoo.com (B.A.-H.); yammunfei@yahoo.com (M.F.Y.);
Tel.: +60-1114014532 (B.A.-H.); +60-164838692 (M.F.Y.)
Academic Editor: Yu-Jia Chang
Received: 13 March 2016; Accepted: 15 April 2016; Published: 25 April 2016
Abstract: Background: Gongronema latifolium Benth. (GL) possesses considerable glucose lowering
effects able to be utilized on a large-scale. This paper investigates the effects of a Soxhlet extract on
hyperglycemia, Langerhans islets and glucose uptake by abdominal muscles. Methods: Ethanol and a
Soxhlet apparatus were used to obtain GL ethanolic Soxhlet extract (GLES). It was then administered
to randomly-segregated male Sprague-Dawley, normal and STZ-induced diabetic rats, using oral
gavage to evaluate blood glucose levels (BGLs), serum lipid profile, insulin levels and the pancreas
post-treatment. Results: GLES significantly (p < 0.05) decreased BGLs of normal rats in glucose
tolerance testing at a dose of 2 g/kg b.w. but failed to do so in diabetic rats undergoing acute 7-h
treatment. Given twice-daily, 1 g/kg b.w. of GLES moderately controlled diabetic BGLs starting from
day 10. After 14 days of treatment, 1 g/kg and 0.5 g/kg b.w. of GLES caused 44% and 50% respective
increases in the average area of Langerhans islets compared to DC. Using isolated rat abdominal
muscle, GLES was found to be a mild insulin-sensitizer. GC-MS analysis revealed the presence
of the known glucose-lowering phytosterol, Sitostenone. Conclusion: Despite retaining moderate
antidiabetic activity, Soxhlet extraction of Gongronema latifolium probably leads to the destruction of
active heat-liable compounds.
Keywords: soxhlet extractor; Gongronema latifolium; diabetes mellitus; hyperglycemia; langerhans
islets; streptozotocin; sitostenone
1. Introduction
Diabetes Mellitus (DM) is a medical condition marked by hyperglycemia arising from lost control
over blood glucose homeostasis. As projected in 2013 by the World Health Organization (WHO),
DM is expected to become the seventh leading cause of death in 2030. According to the Malaysian
Ministry of Health, there were more than 3,000,000 Malaysians suffering from DM in 2011. This is
alarming because the number of DM patients in the Western Pacific Region is expected to double
within the next two decades (WHO). Treatment for Type 2 DM, a multifactorial disease, includes
many different, expensive combinations of drugs whose pharmacokinetic properties, secondary failure
rates and many accompanying side effects often make their continued use problematic [1]. They are
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associated with weight gain, increased risk of hypoglycemia and increased risk of mortality [2]. This
has driven research towards exploring natural alternatives and complementary medicines that have
similar capabilities and less adverse effects or costs. Several African and Asian traditional medicinal
herbs have been screened and scrutinized [3,4]. In South Africa alone, 28 taxa were found to have
reported antidiabetic activity, with more than one of the most popular herbs in ethnomedicine being of
the family Apocynaceae [5].
Gongronema latifolium Benth. (Apocynaceae) is a perennial edible shrub with a soft stem. The
leaves are usually simple, opposite or occasionally whorled with no clear stipules [6]. It is widely
used in the West African sub-region for a large number of medicinal and nutritional purposes [7] and
to treat a variety of ailments, such as hypertension, diabetes mellitus, malaria, mental and intestinal
disorders [8,9]. Traditionally, the leaves of Gongronema latifolium (GL) were cooked as a vegetable soup
for diabetes [10]; and in some African cultures, it is utilized as a spice to support the pancreas [11].
Early reports [9,12] justified GL’s traditional use because it ameliorated the oxidative stress which
accompanied DM and underlined many of the complications of diabetes. Recent reports [7,13–16]
have confirmed the anti-hyperglycemic activity of GL and found it to be superior to that of Nauclea
latifolia [17] and comparable to that of Vernonia amygdalina [18]. The extract has also been incorporated
in a commercialized antidiabetic product in the United States [7]; and decoctions of the plant have
been tested on human subjects [14]. The herb seems to have the prospect of being exploited by the
pharmaceutical industry locally, in Nigeria and globally.
Although extraction of an herbal material can be achieved in many ways, such as mechanical
pounding, decoction, maceration, pressurized-liquid extraction, microwave-assisted extraction,
etc. [19], preparing an extract outside the scope of pilot studies often calls for the use of heat [20].
Soxhlet extraction gives greater extraction efficiency than other methods [21]. This study is aimed to
evaluate the effect of a Soxhlet leaf ethanolic extract of GL on blood glucose levels upon acute and
sub-chronic administration in diabetic rats. The extract‘s effects on serum lipid profile, kidney function
indices and insulin-secreting cells (Langerhans islets) were also examined. Furthermore, this work
explored the effect of GL on in vitro insulin and glucose transduction in isolated rat abdominal muscle
and jejunum.
2. Materials and Methods
2.1. Plant Material
Gongronema latifolium Benth. (Apocynaceae), locally known in Nigeria as Utazi or Arokeke, was
collected as whole plant from Cross River State at the following GPS coordinates (6˝08117.35” N
8˝41115.54” E elev 420 ft) under the supervision of the Department of Biochemistry at the University of
Calabar (Calabar Municipal, Nigeria). Authentication was carried out by Pastor Frank, a botanist in the
Department of Botany, and voucher specimen (ERU/2011/718) was deposited at the same department.
GL leaves were washed and dried in the shade. They were cut into small pieces and ground into fine
powder. No special treatment was performed as GL leaves were reported to have synergistic effects
amongst their constituents [22]. The powder was properly packaged and arrived within 7 days in the
Department of Pharmacology, Universiti Sains Malaysia via courier (Georgetown, Malaysia). Once the
powder was received, it was refrigerated at 4 ˝C until further use.
2.2. Preparation of Extract
The dried leaves (~400 g) were placed in a Soxhlet apparatus with ethanol, which was then
heated to reflux. The choice of the solvent was to yield the most active extract [23] with documented
advantageous properties [9,24]. The heater was set at 60 ˝C and extraction continued over three days
(~50–60 cycles). Anti-pumping silicon granules were added each day before the apparatus was turned
on. The extract was filtered and evaporated at 40 ˝C in vacuo. It was then placed in an oven (45 ˝C)
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until completely dried. The total dry extract, referred to as GLES, amounted to a yield of ~12% and
was refrigerated at 4 ˝C until further use.
2.3. Experimental Animals
Male Sprague-Dawley (SD) rats, weighing initially between 180–220 g, were collected from the
Animal Research and Service Center, Main Campus, Universiti Sains Malaysia (USM), Penang. Prior
to experimentation, the animals were acclimatized to laboratory conditions for one week at the
Animal Transit Room, School of Pharmaceutical Sciences, USM. The rats were kept under standard
environmental conditions (temp.: 25˘ 5 ˝C; RH: 50%˘ 5%; 12-h light/dark cycle). They had ad libitum
access to tap water and standard food pellets (carbohydrates 51%; protein 23%; fat 11%; fibers <5%;
Ash (minerals) 8%; vitamins <1%) obtained from Gold Coin Feedmills Sdn. Bhd., Butterworth, Penang,
Malaysia. The study was approved by the Animal Ethics Committee of the School of Pharmaceutical
Sciences, USM (Approval number: USM/Animal Ethics Approval/2013/(90)(509)).
2.4. Induction of Diabetes
To induce diabetes in rats, a single intraperitoneal (IP) injection of streptozotocin (STZ) (55 mg/kg)
from Sigma-Aldrich (St. Louis, MO, USA) was administered after a 12-h fast. The injected solution
had been freshly prepared by reconstituting STZ in cold normal saline. The diabetic condition
was confirmed 72 h afterwards by checking the fasting blood glucose (FBG) level using Accu-Chek
Performa® glucometer (Roche Diagnostics, Mannheim, Germany). A drop of blood was drawn from
a single puncture of the tail vein. Rats with FBG within 15.0–20.0 mmol/L (270–360 mg/dL) were
included in the study (approx. 60% of all induced animals).
2.5. Experimental Design
2.5.1. Oral Glucose Tolerance Test (OGTT) in Non-Diabetic Rats
After an overnight fast, twenty normal male SD rats were equally divided into four groups
(n = 5), and FBG was determined. Next, the negative control group (NC) was given 10 mL/kg b.w. of
distilled water by oral gavage. The positive control group (PC) received 500 mg/kg b.w. of metformin
(Glucophage®, Bristol-Myers Squibb, New York, NY, USA) grinded in a suitable amount of distilled
water using a mortar and a pestle followed by ultra-sonication (UC-10 Ultrasonic Cleaner, Jeiotech,
Seoul, Korea) for 15 min at 37 ˝C. The extract was reconstituted in distilled water and two different
solutions were prepared to enable the administration of 1 and 2 g/kg b.w. of GLES to the two remaining
treatment groups, TG1 and TG2, respectively. The volume given per os to all animals was similar to the
control. Half an hour later, blood glucose levels (BGLs) were determined, just before an oral glucose
load (500 mg/kg b.w.) at 0 h. Then, BGLs were measured at 15, 30, 45, 60, 90, and 120 min afterwards.
All blood glucose measurements were carried out by using Accu-Chek Performa® (Roche Diagnostics,
Mannheim, Germany).
2.5.2. Acute Treatment in STZ-Induced Diabetic Rats
Following a 12-h fast, twenty five diabetic rats were equally divided into five groups (n = 5).
Additionally, five non-diabetic rats were also fasted and served as the non-diabetic control group.
Grouping and treatment illustration can be found in Table 1. All treatments were given by oral gavage
and distilled water was used as the solvent. FBG was measured before treatment and BGLs were
determined at 1, 2, 3, 5, and 7 h by using Accu-Chek Performa® (Roche Diagnostics, Mannheim,
Germany). Blood was obtained via a vein puncture at the tip of the tail.
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Table 1. Animal Grouping: Acute treatment with Gongronema latifolium extract.
Group Treatment
TG1 500 mg/kg b.w. of GLES
TG2 1000 mg/kg b.w. of GLES
TG3 2000 mg/kg b.w. of GLES
Diabetic Control (DC) 10 mL/kg b.w. of distilled water
Positive Control (PC) 500 mg/kg b.w. of metformin
Non-Diabetic Control (NC) 10 mL/kg b.w. of distilled water
2.5.3. Sub-Chronic (14 Days) Treatment (Twice-Daily) in STZ-Induced Diabetic Rats
Following a 12-h fast, thirty diabetic rats were equally divided into five groups (n = 6).
Additionally, six non-diabetic rats were also fasted and served as the non-diabetic control group.
Grouping and treatment illustration can be found in Table 2. All treatments were given twice-daily
p.o. by using distilled water as the solvent. BGLs were determined on day 1 (before treatment) and
days 4, 7, 10, and 15 (after treatment) by using Accu-Chek Performa® (Roche Diagnostics, Mannheim,
Germany). Blood was obtained via a vein puncture at the tip of the tail.
Table 2. Animal Grouping: Sub-chronic treatment with Gongronema latifolium extract.
Group Treatment
TG1 250 mg/kg b.w. of GLES
TG2 500 mg/kg b.w. of GLES
TG3 1000 mg/kg b.w. of GLES
Diabetic Control (DC) 10 mL/kg b.w. of distilled water
Positive Control (PC) 500 mg/kg b.w. of metformin
Non-Diabetic Control (NC) 10 mL/kg b.w. of distilled water
2.5.4. Serum Biochemical Parameters
Following the 14-day treatment, the animals were anesthetized and blood was collected via
cardiac puncture (~5 mL) into plain tubes. To separate the sera, the samples were allowed to clot
for 30 min and were centrifuged at 2500 rpm for 15 min. Separated into two portions, the sera were
stored at ´20 ˝C until further use. Lipid profile and kidney function parameters were determined at a
local reference laboratory, Gribbles Pathology. Serum lipid profile was determined using ADVIA 2400
Chemistry Analyzer (Siemens, Erlangen, Germany). Kidney function parameters were analyzed by
using Olympus AU640 Chemistry Immuno-Analyzer (Olympus, Tokyo, Japan). The concentration of
serum insulin was determined by using an ultra-sensitive rat insulin ELISA kit (Crystal Chem Inc.,
Illinois, IL, USA) with inter- and intra-assay precision of CV ď10 as per the manufacturer’s handbook.
2.5.5. Histopathological Studies
At the end of sub-chronic treatment, the rats were sacrificed and dissected. The pancreas was
removed, weighed and fixed in 10% buffered formalin for seven days. The pancreatic tissue was then
dehydrated with a series of alcohols, chloroform and liquid paraffin at 58 ˝C before being embedded
in paraffin. The fixed pancreatic tissues were sectioned (5-micron thickness) and the sections were
specifically stained by the Aldehyde Fuschin procedure introduced by Gomori [25]. The stained tissue
was evaluated by examination of 10 islets per group by using a Leica MZ6 optical microscope (Leica
Microskopie und Systeme, Wetzlar, Germany) equipped with a Leica Qwin (Leica Imaging Systems,
Cambridge, England).
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2.6. Glucose Uptake by Isolated Rat Abdominal Muscle
The uptake of glucose by isolated abdominal muscle was measured according to the method
developed by Gray and Flatt [26] with modifications [27,28]. Rats weighing between 180 and 220 g
were sacrificed and their abdominal muscles extracted. Each muscle was cut into small squares
(90–150 mg), weighed and left in a Krebs-Ringer bicarbonate (KRB) buffer (KRB: 118 mmol NaCl/L,
25 mmol NaHCO3/L, 5 mmol KCl/L, 1.28 mmol CaCl2/L, 1.2 mmol MgSO4/L, and 1.0 mmol
KH2PO4/L) in the presence of 95% O2 and 5% CO2 at 37 ˝C. After 10 min, the muscles were transferred
to pre-labeled 1.5 mL Eppendorf tubes filled with KRB solution containing 11.1 mmol D-glucose/L.
GLES had been added to the tubes (1 mg/mL) in the presence and absence of 1 IU/mL insulin.
The final volume was 1 mL. The muscles were aerated for 5 min and incubated for 30 min at 37 ˝C
and then removed. Next, 30 µL from each tube was added to 3 mL of peridocrome (Boehringer,
Mannheim, Germany). The final solutions were incubated at 37 ˝C for 20 min and measured by using
a chemistry analyser, Stat Fax 1937 (Awareness Technology Inc., Palm City, FL, USA). Glucose uptake
was expressed as mg Absorbed Glucose/g Muscle.
2.7. Glucose Absorption via Isolated Rat Jejunum
Rats weighing between 180–220 g were sacrificed and their abdominal walls dissected. The
jejunum (20 cm to 50 cm away from the pylorus) was removed and everted according to Wilson and
Wiseman [29] as described by Yusoff, et al. [30]. Everted jejuna were cut into 5-cm segments and put
into an oxygenated Tyrode solution (137 mmol NaCl/L, 2.7 mmol KCl/L, 1.8 mmol CaCl2/L, 1.0 mmol
MgCl2/L, 12.0 mmol NaHCO3/L, 0.2 mmol NaH2PO4/L, and 5.5 mmol D-glucose/L). Each segment
was filled with 0.5 mL of Tyrode and tied at both ends to form a sac. Tubes were filled with 15 mL
of Tyrode and gassed with 95% O2 and 5% CO2 at 37 ˝C. The sacs were incubated inside the tubes
for a period of 90 min. An equal number of tubes contained 1 mg/mL Phlorizin (Sigma-Aldrich,
Milwaukee, WI, USA), 1 mg/mL Acarbose (Sigma-Aldrich, Milwaukee, WI, USA), and 1 mg/mL
of GLES. Tubes with the Tyrode solution alone served as the negative control. The concentration of
glucose was measured before and after incubation by using Stat Fax 1937 (Awareness Technology
Inc., Palm City, FL, USA). The amount of glucose transported was calculated based on the glucose
remaining outside of the sacs. It was expressed as mg Absorbed Glucose/g Tissue.
2.8. Gas Chromatography-Mass Spectrometry (GC-MS)
GLES was prepared in a 5 mg/mL solution using absolute ethanol as the solvent (blank). The
sample was analyzed using GC Agilent 6890N/95731 equipped with quadrupole Mass Spectrometer.
The capillary column used was an Agilent column (HP-5MS: 122-5532) with designated dimensions
(30 m ˆ 0.25 mm ˆ 0.25 µm). Helium (99.999%) was used as the carrier gas (mobile phase) with a flow
rate of 1.2 mL/min set to split mode. An aliquot of 1 µL of the sample was injected into the column.
The injector was pre-heated to 280 ˝C. GC oven temperature started at 50 ˝C and rose to 280 ˝C at the
rate of 20 ˝C/min without holding. Holding was allowed at 280 ˝C for 20 min. The MS quadrupole
and ion source were set at 150 ˝C and 230 ˝C, respectively. The mass spectrum of the compounds in
the sample was obtained by the standard electron ionization of 70 eV. The detector was operated in
scan-mode to detect molecules in the range of 35–650 amu. Analysis time was 33.50 min. Mass spectra
were analyzed using the database of the National Institute of Standards and Technology (NIST 02).
Chemical structures and information related to molecular formulas, and activities were obtained using
Chemspider, the online database of the Royal Society of Chemistry, UK.
2.9. Statistical Analysis
Results were expressed as the mean˘ SEM. Statistical significance was investigated using version
21 of the IBM-SPSS statistical program (IBM Corp., Armonk, NY, USA). One-way ANOVA was used
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followed by Dunnett’s Test as a Post Hoc Test. Pre-treatment and post-treatment comparisons were
performed using the paired t-test. Differences were considered significant when p < 0.05.
3. Results
3.1. Oral Glucose Tolerance Test (OGTT) in Normal Rats
In comparison with NC, administration of metformin significantly (p < 0.05) reduced BGLs at
minute 30 (Figure 1). Furthermore, after glucose loading, PC showed significantly (p < 0.001) lower
glucose levels at minutes 15, 30, 45, 60, and 90. Similarly, TG2 showed significantly (p < 0.05) lower
BGLs at minute 45 compared with NC.Med. Sci. 2016, 4, 2 6 of 15 
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BGLs. NC showed rather normal glucose levels with the difference in blood glucose remaining as 
significant (p < 0.001) compared with DC throughout the experiment. 
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3.3. Sub-Chronic (14 Days) Treatment in STZ-Induced Diabetic Rats 
When diabetic SD rats were treated twice-daily for 14 days with GLES, the effect was 
comparable, yet inferior to metformin: Both metformin (500 mg/kg) and GLES (1000 mg/kg) 
ameliorated hyperglycemia and induced significantly (p < 0.05) lower BGLs starting from day 10 
(Figure 3). A transient significant reduction of BGLs was also observed in TG1. Comparison of BGLs 
before and after treatment showed that when given twice-daily, 1 g/kg b.w. of GLES lowered BGLs 
as efficiently as 500 mg/kg b.w. of the conventional medicine, metformin (p < 0.01) (Figure 4). 
Figure 1. Oral Glucose Tolerance Test with Gongronema latifolium extract in normal rats (n = 5). Values
are expressed as the mean ˘ SEM, * = p < 0.05; *** = p < 0.001 vs. NC.
3.2. Acute (7-h) Treatment i STZ-Induced Diabetic Rats
Starting from hour 3 post-treatment, PC showed significantl ( . 1) reduced BGLs (Figure 2).
Metformin continued to lower BGLs significantly compared with DC throughout the observation
period (p < 0.05). GLES administered up to a single dose of 2000 mg/kg did not influence diabetic
BGLs. NC showed rather normal glucose levels with the difference in blood glucose remaining as
significant (p < 0.001) compared with DC throughout the experiment.
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Figure 2. Acute (single) treatment with Gongronema latifolium extract in STZ-induced diabetic rats
(n = 5). Values are expressed as the mean ˘ SEM, * = p < 0.05; ** = p < 0.01; *** = p < 0.001 vs. DC.
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3.3. Sub-Chronic (14 Days) Treatment in STZ-Induced Diabetic Rats
When diabetic SD rats were treated twice-daily for 14 days with GLES, the effect was comparable,
yet inferior to metformin: Both metformin (500 mg/kg) and GLES (1000 mg/kg) ameliorated
hyperglycemia and induced significantly (p < 0.05) lower BGLs starting from day 10 (Figure 3).
A transient significant reduction of BGLs was also observed in TG1. Comparison of BGLs before and
after treatment showed that when given twice-daily, 1 g/kg b.w. of GLES lowered BGLs as efficiently
as 500 mg/kg b.w. of the conventional medicine, metformin (p < 0.01) (Figure 4).
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3.3.1. Gongronema latifolium Subchronic (14 Days) Treatment Effects on Body Weight and Food Intake
(kcal/g b.w./day)
Weight changes were monitored throughout the period of the experiment. The increase in the
weight of the normal rats was significant (p < 0.001) compared to th diabetic control group starting
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from day 6 until the end of the study. On the other hand, when compared to DC, GLES caused no
significant changes in body weight. Initial levels of food consumption were also measured at the
beginning of the 14-day treatment and on days 5, 10, 11, 12 and 13. Food intake was calculated based on
the feed’s metabolizable energy value as provided by the supplier. It was presented as kcal/g b.w./day
(Figure 5). Compared to DC, the normal rats maintained a significantly lower energy consumption
(food intake) rate. However, except for day 13, changes of food intake of the extract-treated groups,
TG1, TG2, and TG3 showed no significant differences compared to DC. Probably signaling better
glycemic control, food intake tended to decrease with the administration of metformin (PC) after day
10. The difference was significant on day 13 compared with DC (p < 0.05).
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Figure 5. Percentage of change in food intake (kcal/g b.w./day) during sub-chronic treatment with
Gongronema latifolium extract. Values are expressed as the mean ˘ SEM, * = p < 0.05; ** = p < 0.01;
*** = p < 0.001 vs. DC.
3.3.2. ongrone a latifoliu Subchronic (14 ays) reat ent Effects on Seru Bioche ical Para eters
o pare to the iabetic control ( ) after 14 ays of treat ent, S (1 g/kg) increase
significantly (p 0.001). TG3 total cholesterol and L levels ere significantly (p 0.001) higher
co are ith . itionally, bot 2 a 3 s o e lo er bloo riglyceri e levels i a
o -sig ifica t a er. o observable change in the LDL levels was recorded in the treated groups.
n the other han , signaling an impaired renal function, urea was significantly (p < 0.001) higher in all
of the diabetic groups as compared to NC. The findings indicated that consecutive administration of
GLES to diabetic rats in doses up to 1000 mg/kg t ice-daily for 14 ays i ot affect t e le els of
bloo electrolytes, creati i e, or ric aci . Those findings ight be in support of [13] i ter s of
re o rotecti e ro erties i iabetes.
3.3.3. Serum Insulin Measurement
Comparison between NC and DC showed that administration of streptozotocin significantly
reduced the level of circulating insulin in the blood (p < 0.001) (Figure 6). This highlighted the damage
to pancreatic β-cells. However, treatment with metformin (500 mg/kg) and GLES (1000 mg/kg) for
14 days resulted in a significant (p < 0.05) positive impact on insulin levels, probably due to marked
reduction of BGLs and improvement in animals’ welfare. This is in contrast with Coscinium fenestratum
of the traditional Ayurveda and Siddha systems of medicine, whose use in STZ-induced animals
lowered blood glucose levels but had no impact on serum insulin levels [31]. The effects observed here
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corresponded with further findings that indicated a structural recovery in Langerhans islets following
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3.3.4. Assessment of the Area of Pancreatic β-cell-Containing Langerhans Islets
At the end of the 14 days, the animals were sacrificed and the pancreases removed. All pancreatic
tissues were h dled as describ d ea lier and th roughly examined (Figur 7). Compared to DC,
Langerh ns islets n the pancr atic tissues f the non-diabetic rats (NC) were nearly twice as large. The
difference between the two groups was significant (p < 0.01). GLES at 1000 and 500 mg/kg b.w. caused
44% and 50% respective increases in the average area of Langerhans islets compared to DC. Compared
with NC, GLES (500 and 1000 mg/kg) yielded Langerhans islets that were ~80% as large. This effect
was not observed when metformin (500 mg/kg) was administered with the same frequency.
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Figure 7. Langerhans islets under 400ˆ magnification power. (1) NC: langerhans islets are clearly
defined in an organized cyto-architectur . Secreto y acini, centroacinar cells and excretor d appear
to be well defined; (2) DC: Cytotoxic effects of Streptozotocin seem to have caused a distortion in the
architecture of the pancreatic tissues. The islets are greatly reduced in size and number and the islet
cells appear necrotic with marked vacuolations; (3) PC: cyto-architecture appears distorted. Langerhans
islets are reduced in size and number, with necrotic acinar cells and degenerat slet cells; (4) TG1:
Langerhans Islets appear to be small, with minor vacuolations and cyto-architecture distortio ; (5) TG2:
Langerhans Islets appear be large an defined. Minor vacuola ions a d yto-archite ture distortion
are present. Secretory acini, centroacinar cells and excretory ducts appear to be well defined; (6) TG3:
Islet cells appear to be prominent and large. Edges seem to be well defined.
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3.4. Effect of G. latifolium Extract on Muscle Glucose Uptake and Jejunum Glucose Absorption
Rat abdominal muscle segments were isolated, weighed and incubated at 37 ˝C. Glucose uptake
by each segment was calculated as previously described. When introduced to the muscles in vitro,
both GLES and insulin did not increase the uptake of glucose by much. However, when combined, the
effect was more than each one alone, indicating mild insulin-sensitization activity (Table 3). To observe
the effect of GLES on glucose absorption via the intestinal tract, rat jejunum sacs were prepared and
calculations made as described earlier. Both Phlorizin and Acarbose were shown to reduce glucose
active transport via rat jejunum sacs (Table 4). On the other hand, intestinal glucose transport was not
influenced by GLES. Hence, it may be safely concluded that the decrease in postprandial BGL caused
by the extract, as shown earlier in OGTT (Figure 1), did not result from delayed glucose absorption via
the intestinal tract.
Table 3. Effect of an ethanolic extract of Gongronema latifolium on glucose uptake by isolated rat
abdominal muscle incubated in the presence/absence of insulin (mg glucose/g tissue) (n = 5).
Control Insulin (1 IU/mL) GL (1 mg/mL) Insulin + GL
285.2 ˘ 10.81 328.52 ˘ 9.43 319.87 ˘ 29.41 392.54 ˘ 34.16
Table 4. Effect of an ethanolic extract of Gongronema latifolium on glucose active transport via isolated
rat jejunum (n = 6).
Control Phlorizin (1 mg/mL) Acarbose (1 mg/mL) GL (1 mg/mL)
52.62 ˘ 13.66 22.32 ˘ 9.94 21.78 ˘ 6.87 50.58 ˘ 11.52
3.5. GC-MS Analysis of GLES
In this study, GC-MS analysis showed GLES to contain 15 volatile compounds with high certainty
(Table 5). It was found to be mainly rich in saturated fatty acid esters, such as Methyl Palmitate, Methyl
Stearate and Methyl Arachidate; and long chain hydrocarbons such as Nonacosane and Palmitic Acid.
It also contained an unsaturated fatty acid ester, Methyl Oleate and an unsaturated fatty alcohol,
linolenyl alcohol. Phytol, D:C-friedoolean-8-en-3-one and stigmast-4-en-3-one (sitostenone) were
amongst the major volatile compounds found in GLES.
Table 5. GC-MS spectral analysis of ethanolic extract of Gongronema latifolium.
No. RT (min) Name of the Compound MolecularFormula Peak Area % Quality
1 3.15 Triethyl borate C6H15BO3 0.51 95
2 11.62 Methyl Palmitate C17H34O2 11.28 98
3 11.87 Trichloroacetic acid, hexadecyl ester C18H33Cl3O2 0.41 87
4 11.95 Ethyl Palmitate C18H36O2 2.46 95
5
12.00
Palmitic acid C16H32O2
2.52 94
12.03 3.86 95
12.10 5.71 95
6 12.43 Methyl Oleate C19H36O2 5.32 99
7 12.46 Linolenyl alcohol C18H32O 3.40 97
8 12.52 Methyl stearate C19H38O2 2.53 99
9 13.01 Phytol C20H40O 20.53 91
10 13.42 Methyl Arachidate C21H42O2 1.53 97
11 14.30
Octadecanoic acid, 10-methyl-, methyl
ester,(R) C20H40O2 0.69 94
(or) Methyl Behenate C23H46O2
12 16.66 Nonacosane C29H60 5.48 98
13 18.82
Eicosane C20H42 7.01 95(or) Hentriacontane C31H64
14 24.3 D:C-Friedoolean-8-en-3-one C30H48O 12.35 87
15 26.41 Stigmast-4-en-3-one (Sitostenone) C29H48O 6.64 98
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4. Discussion
Gongronema latifolium is an herbaceous shrub with yellow flowers [13] referred to as utazi and
arokeke in South Eastern and South Western Nigeria, respectively [9]. It is widespread in the tropical
and subtropical regions especially in Africa and South America, with a moderate representation in
Northern and South Eastern Asia [32]. The LD50 of an extract of GL given by the intraperitoneal route
was found to be 1678.63 ˘ 78 mg/kg b.w. in mice [33] and the oral LD50 was estimated to be greater
than 5000 mg/kg b.w. in albino rats [34]. In the present study, the doses of GLES administered to the
SD rats were between 500–2000 mg/kg b.w/day.
Rising longevity, consumption of calorie-rich diets, obesity and a sedentary lifestyle has led
to a marked increase in the number of diabetics worldwide [35] and contributed to the growing
interest among researchers to investigate the therapeutic potential of plants [36]. According to Pouwer
and Hermanns [37], the management of diabetes should focus on three main targets: prevention of
hyperglycemia and its associated complications, prevention of hypoglycemia and maintenance of
the patient’s quality of life. This paper investigated the antihyperglycemic activity of Gongronema
latifolium upon acute and subchronic treatments; and the results confirmed the antihyperglycemic
activity observed earlier by Ugochukwu and Babady [23], but using a greater dose. This implied that
Soxhlet extraction may have affected the antihyperglycemic potential of GL by way of lost heat-labile
active principal(s). This is in contrast with the soxhlet extract of West African Morinda lucida leaves,
whose hypoglycemic effect was shown to be superior to tolbutamide, a sulfonylurea, in diabetic rats at
comparatively lower doses than GL in the present study [38]. However, with a complex disorder such
as DM, achieving optimum blood glucose control is only half the solution towards achieving good
quality of life. Currently available oral anti-diabetic drugs often lead to weight gain and cause an obese
condition [39]. Furthermore, DM has been associated with dysregulation of food intake, probably due
to impaired vagal outflow arising from hyperglycemia [40]. As observed in this present study, GLES
had no negative impact on body weight and food intake rates in diabetic rats.
Dyslipidaemia is a common manifestation in DM cases and is associated with greater risk of
atherosclerosis because of increased levels of triglycerides, VLDL and LDL, presence of small dense
LDL particles and decreased HDL levels [41]. STZ-induced diabetic rats presented with elevated
blood cholesterol and triglyceride levels [42]. In this study, the diabetic animals which received
1 g/kg of GLES sub-chronically developed high total cholesterol levels (TC), although they had
close-to-normal TC/HDL ratios, also referred to as the Cardiac Risk Ratio (CRR) [43], indicating a clear
elevation in the serum HDL levels. This activity of GLES could prove to be valuable in countering
premature atherosclerosis associated with Type 2 DM. This proposition is in tandem with that of
Brai, et al. [44] about the observed effect of leaf extracts of Persea Americana on lipid metabolism in
hypercholesterolemic rats. On the other hand, as opposed to Ugochukwu, Babady, Cobourne and
Gasset [9], GLES had no reducing effect on LDL levels in any of the treated groups. This lost effect
perhaps signals lost heat-labile active principal(s) as the report cited above utilized a cold extraction
method to prepare GL ethanolic extract. Lastly, in agreement with [45], reductions in the levels of TC
and LDL caused by metformin were rather small. Present data also showed that daily doses of GLES as
high as 1000 mg/kg b.w. had no significant effect on the levels of the renal function parameters tested.
The understanding of the mechanisms which underlie GL’s antihyperglycemic effect is still lacking.
Possible mechanisms of action have been suggested. The effect was attributed to an insulin-like activity
of the ethanolic extract [23] and more recently an insulinotropic activity [22]. Ogbu, et al. [46] attributed
the decrease in BGLs partly to delayed gastric emptying. Our in vitro findings showed that GLES had
no effect on glucose active transport via the intestinal wall. Perhaps, the insulin-sensitizing activity
observed in this work might be one of the mechanisms by which the extract exerts its antihyperglycemic
effect, especially because such a mechanism seems to be consistent with our findings on the level of
serum insulin following the 14-day treatment.
Langerhans islets are found in the exocrine acinar cells of the pancreas and are composed of
several endocrine cells: α-cells, β-cells, δ-cells, and PP-cells [47]. β-cells constitute the major cell type
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(occupying 70%–80%) in an islet [48] and are responsible for insulin secretion in response to elevated
BGLs. As indicated by our findings and in agreement with [7], unlike metformin, GLES was found
to act directly on the pancreas to induce the regeneration of a tissue that appeared well structured
and Langerhans islets that appeared well defined and larger in area compared with the diabetic
control in a statistically non-significant manner. Nagappa, et al. [49] noted similar partial restoration
of normal cellular population when investigating Indian Almond, Terminalia catappa. This probably
translated into the observed higher serum insulin levels in TG3 compared with DC in this study.
Nevertheless, the current results ought to be considered within the context of some limitations: Diabetes
mellitus was induced in the animals by partial destruction of pancreatic cells, especially β-cells, using
a dose of bacteria-derived Streptozotocin (STZ), a substance which is known to cause oxidative
stress [50]. However, the antioxidant components present in GL extracts are so chemically diverse
that both chlorophyll-enriched and chlorophyll-depleted fractions were found to possess considerable
antioxidant properties [24]. Hence, what might have been perceived as restoration of Langerhans
islet area could have been a result of GL’s established antioxidant potential [9,51] countering further
oxidative damage caused by STZ. Furthermore, although our findings suggested that GLES increased
the average area of Langerhans islets up to 50% compared to DC, Gomori stain remained insufficient
to determine the viability of the β-cells within those islets. Further research is necessary to validate
our conclusions using more advanced staining techniques of immunohistochemistry [27].
Over the past two decades, different parts of Gongronema latifolium have been found to contain
saponins, anthraquinones, alkaloids, β-sistosterol, lupenyl esters, pregnance ester, glucosides and
essential oils [10,52]. Indicating possible synergism between its components, the crude methanolic
extract was reported to have a higher antihyperglycemic activity in vivo than its individual fractions
and a comparable insulinotropic effect to glibenclamide [22]. Literature seems to indicate that GL acts
to stimulate the secretion of insulin from the pancreas via non-phenolic molecules, as the methanol
used by Fasakin, Udenigwe and Aluko [24] probably resulted in an extract that was poor in phenolic
compounds. The active principles responsible for GL antidiabetic effect are yet to be fully characterized.
In the current study, Stigmast-4-en-3-one, also known as Sitostenone, was found to be present in GLES.
It is an active phytosterol which possesses an activity against NO release [53] and has been implicated
in the hypoglycemic effects of a couple of herbal extracts [54,55]—possibly making it one of the
chemical entities responsible for the moderate blood glucose lowering effect of GLES observed in this
work. Some fatty acids such as those found in GL extracts have been strongly implicated in known
anti-diabetic mechanisms [56]. Further research is still needed to elucidate the components of these
extracts using more elaborate techniques like HPLC and IR.
5. Conclusions
Gongronema latifolium Benth. (Apocynaceae) displayed a moderate significant blood glucose
lowering effect with high daily doses in sub-chronic treatment in the present study. Although the
tested extract produced a significantly improved lipid profile and mild regenerative effect at the level
of the pancreas, among other beneficial aspects, we speculate that Soxhlet extraction might have
contributed to the loss of valuable heat-labile active principles from the plant. The activity retained
by our extract however, should indicate the presence of heat-stable active principles as well, such as
Sitostenone, a glucose lowering agent that we report as one of the major volatile compounds present
in G. latifolium.
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Abbreviations
The following abbreviations are used in this manuscript:
GL Gongronema latifolium
GLES Gongronema latifolium ethanolic Soxhlet extract
DM Diabetes mellitus
STZ Streptozotocin
FBG Fasting blood glucose
BGLs Blood glucose levels
b.w Body weight
SD Sprague-Dawley
GC-MS Gas chromatography-mass spectrometry
NC Normal control
DC Diabetic control
PC Positive control
TG Treatment group
WHO World Health Organization
OGTT Oral glucose tolerance test
LDL Low-density lipoproteins
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LD50 Median lethal dose
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